Choose Your News
Loading...
Tags:
Thumbnail
Takeda Pharmaceutical Company Limited (TSE: 4502) gab heute bekannt, dass der Ausschuss für Humanarzneimittel (CHMP) der Europäischen Arzneimittel-Age... [Read More]
Thumbnail
A leading investor in the Japanese pharmaceuticals giant Takeda is "sceptical" of the planned $62bn (£47bn) takeover of Shire, the FTSE 100 rare disease specialist.... [Read More]
Thumbnail
Takeda Pharmaceutical Company Limited (TSE: 4502) anunció hoy que el Comité de Productos Medicinales para Uso Humano (CMHP) de la Agencia Europea de M... [Read More]
Thumbnail
Takeda Pharmaceutical Company Limited (TSE: 4502) anunciou hoje que o Comitê de Medicamentos para Uso Humano (CHMP) da Agência Europeia de Medicamento... [Read More]
Thumbnail
Takeda Pharmaceutical Company Limited (TSE: 4502) oggi ha annunciato che il Comitato per i medicinali per uso umano (CHMP) dell'Agenzia europea del fa... [Read More]
Thumbnail
Overview More than 30,000 Takeda employees working in more than 70 countries are committed to improving quality of life for patients, who remain at... [Read More]
Thumbnail
Overview More than 30,000 Takeda employees working in more than 70 countries are committed to improving quality of life for patients, who remain at... [Read More]
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of t... [Read More]
Opinions released today from the European Medicines Agency's advisory group CHMP. Positive: Takeda's (TKPHF)(TKPYY) Alunbrig (brigatinib) for adult patient... [Read More]
— Opinion Based on Pivotal Phase 2 ALTA Trial, in which ALUNBRIG Demonstrated an Objective Response Rate of 56% and Longest Reported Median Progression-Free Survival... [Read More]
CAMBRIDGE, Mass. & OSAKA, Japan -- --Sep 21, 2018--Takeda Pharmaceutical Company Limited ( TSE: 4502 ) today announced that the European Medicines Agency's (EMA) Committee... [Read More]
Takeda Pharmaceutical Co's lung cancer drug received the recommendation of a European Union panel on Friday, more than a year after it won regulatory approval... [Read More]
Even after Wednesday's big move, shares have lost roughly a third of their value thus far in 2018. The new Takeda agreement involves a significant... [Read More]
Molecular Templates saw gains on Wednesday after announcing that it has extended its partnership with Takeda. The company had a decent amount of funding at... [Read More]
Molecular Templates (MTEM) signs a collaborative contract with Japan's Takeda for jointly developing CD38-targeted engineered toxin antibodies to treat multiple myeloma. The stock soars past... [Read More]
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of t... [Read More]
About the team/job An exciting opportunity has been created for a talented data scientist/text miner to work on project on text mining methods for the... [Read More]
Gainers Molecular Templates Inc (NASDAQ: MTEM) shares jumped 77.8 percent to $7.29 after the company announced an agreement with Takeda for joint ... [Read More]
Thinly traded micro cap Molecular Templates (MTEM) is up 41% premarket on increased volume in response to its deal with Takeda Pharmaceutical (TKPYY)(TKPHF... [Read More]
Shares of Molecular Templates Inc. ... [Read More]
Loading...
Preview